Biologics

Osbourn has over 30 years’ experience in biologics discovery and development. Most recently, she was Vice President for Research and Development and Site Leader at MedImmune …

Mr. Pollano has more than 25 years of industry experience, including senior management positions in global CDMOs. Federico Pollano succeeds Dr. Christoph Winterhalter, who has left …

The team headed by Devon Taylor identified a set of CD4-positive T-cells, which express the protein inducible costimulator (ICOS) in human skin, which contributes to systemic …

Mr. Larkin brings to SP broad experience as a senior executive having spent the last 27 years in commercial and executive leadership roles in the medical …

The deal includes the  acute lymphoblastic leukemia (ALL) drug pegaspargase (Oncaspar) and late stage ALL candidate drug calaspargase pegol plus the ex-US rights fort a nano-formulation of the …

GMP and new processes: be prepared for hassle Source link

The company reported promising 2-year overall survival data for its RAS mutations-targeting cancer jab TG01. Targovax’ CFO Erik Wiklund presented data showing that 90% of patients …

The takeover of Shire is the largest acquisition in Takeda’s history. Under the agreement, Takeda will pay  US$66, per share US$30.33 in cash and 0.839 Takeda …

Kite’s CD19-targeting CAR-T cell therapy axicabtagene ciloleucel, which received FDA approval in October 2017 to treat B cell lymphomas under the brand name Yescarta, is currently …

EuroBiotech_ Where does Celonic stand today, and where do you want to place your company in the long term?Bracht_The acquisition of Glycotope’s manufacturing business we announced …